By Denny Jacob
EyePoint Pharmaceuticals shares slide 32% after disclosing that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't...
Related Keywords
Denny Jacob , Eyepoint Pharmaceuticals , Point Pharmaceuticals , Dow Jones , Markets ,
comparemela.com © 2020. All Rights Reserved.